Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents (Q34257845)

31 July 2017

1 reference

title

Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents (English)

1 reference

31 July 2017

carbapenem antibiotic

0 references

author name string

Sader HS

series ordinal

1

1 reference

PubMed ID

11368281

31 July 2017

Gales AC

series ordinal

2

1 reference

31 July 2017

1 January 2001

1 reference

31 July 2017

1 reference

31 July 2017

61

1 reference

31 July 2017

5

1 reference

31 July 2017

553-564

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200161050-00001

31 July 2017

0 references

cites work

Carbapenems in clinical practice: a guide to their use in serious infection

1 reference

12 December 2020

Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997)

1 reference

12 December 2020

Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.

1 reference

12 December 2020

Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects

1 reference

12 December 2020

Sub-MICs of sanfetrinem promote the interaction of human polymorphonuclear granulocytes with a multiply resistant strain of Klebsiella pneumoniae.

1 reference

12 December 2020

Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.

1 reference

12 December 2020

In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).

1 reference

12 December 2020

Synthesis and structure-activity relationships of a novel oral carbapenem, CS-834

1 reference

12 December 2020

Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

1 reference

12 December 2020

Extended-spectrum beta-lactamases

1 reference

12 December 2020

Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents

1 reference

12 December 2020

A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326).

1 reference

12 December 2020

Comparative in vitro activity of biapenem, a new carbapenem antibiotic

1 reference

12 December 2020

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

12 December 2020

Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens

1 reference

12 December 2020

A functional classification scheme for beta-lactamases and its correlation with molecular structure

1 reference

12 December 2020

Stability, tissue metabolism, tissue distribution, and blood partition of DA-1131, a new carbapenem

1 reference

12 December 2020

In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1 beta-methylcarbapenems

1 reference

12 December 2020

In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic

1 reference

12 December 2020

In-vitro activity of sanfetrinem against isolates of Streptococcus pneumoniae and Staphylococcus aureus

1 reference

12 December 2020

In vitro activity of the tribactam GV104326 against gram-positive, gram-negative, and anaerobic bacteria

1 reference

12 December 2020

Interactions of beta-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral beta-lactams.

1 reference

12 December 2020

Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits

1 reference

12 December 2020

In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates

1 reference

12 December 2020

Susceptibility testing of fastidious organisms

1 reference

12 December 2020

Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods.

1 reference

12 December 2020

In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa

1 reference

12 December 2020

Carnitine deficiency induced by pivampicillin and pivmecillinam therapy

1 reference

12 December 2020

MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agents

1 reference

12 December 2020

Synthesis and in vitro activity of a new carbapenem, RS-533

1 reference

12 December 2020

In vitro activity and beta-lactamase stability of LJC 10,627

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem.

1 reference

12 December 2020

Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates

1 reference

12 December 2020

Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats

1 reference

12 December 2020

Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic

1 reference

12 December 2020

Pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field

1 reference

12 December 2020

Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.

1 reference

12 December 2020

Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents

1 reference

12 December 2020

Carbapenems: the pinnacle of the beta-lactam antibiotics or room for improvement?

1 reference

12 December 2020

In vitro activity of the tricyclic beta-lactam GV104326.

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem

1 reference

12 December 2020

In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests

1 reference

12 December 2020

In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I.

1 reference

12 December 2020

Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in São Paulo, Brazil

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of GV129606, a new broad-spectrum trinem

1 reference

12 December 2020

In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria

1 reference

12 December 2020

Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex

1 reference

12 December 2020

Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.

1 reference

12 December 2020

Activity of cefepime and other beta-lactam antibiotics against permeability mutants of Escherichia coli and Klebsiella pneumoniae.

1 reference

12 December 2020

In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria

1 reference

12 December 2020

Pharmacokinetics and tissue distribution of a new carbapenem DA-1131, after intravenous administration to mice, rats, rabbits and dogs

1 reference

12 December 2020

Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes.

1 reference

12 December 2020

Bacterial resistance: a worldwide problem

1 reference

12 December 2020

1 beta-Methyl-2-(5-substituted pyrrolidin-3-ylthio)carbapenems. 3. Synthesis and antibacterial activity of BO-2727 and its related compounds

1 reference

12 December 2020

Evaluation and characterization of multiresistant Enterococcus faecium from 12 U.S. medical centers

1 reference

12 December 2020

Safety and pharmacokinetics of CS-834, a new oral carbapenem antibiotic, in healthy volunteers.

1 reference

12 December 2020

In vitro activity of the trinem sanfetrinem (GV104326) against gram-positive organisms

1 reference

12 December 2020

Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640

1 reference

12 December 2020

Recent advances in the chemistry and biology of carbapenem antibiotics

1 reference

12 December 2020

Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem

1 reference

12 December 2020

In vitro activity of sanfetrinem (GV104326), a new trinem antimicrobial agent, versus Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

1 reference

12 December 2020

Antibacterial properties of BO-2727, a new carbapenem antibiotic

1 reference

12 December 2020

In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I

1 reference

12 December 2020

In vitro activity of L-627, a new carbapenem

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of a new carbapenem BO-2727 for use in obstetrics and gynecology

1 reference

12 December 2020

In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I

1 reference

12 December 2020

Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase

1 reference

12 December 2020

A novel oral carbapenem CS-834: chemical stability of pivaloyloxymethyl esters of carbapenems and cephalosporins in phosphate buffer solution

1 reference

12 December 2020

New mechanisms of bacterial resistance to antimicrobial agents

1 reference

12 December 2020

Biapenem versus imipenem in the treatment of experimental intraabdominal infections

1 reference

12 December 2020

In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae

1 reference

12 December 2020

Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems.

1 reference

12 December 2020

Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-I

1 reference

12 December 2020

In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem

1 reference

12 December 2020

10.2165/00003495-200161050-00001

Identifiers

DOI

1 reference

PubMed ID

11368281

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11368281